Literature DB >> 11126378

Primary liver tumors.

W Y Lau1.   

Abstract

Many improvements have been made in the treatment of primary liver tumors, especially in hepatocellular carcinoma. Partial hepatectomy still remains the mainstay of therapy for resectable tumors, and it offers the potential of a cure. Total hepatectomy and liver transplantation may be applicable in selected patients. Palliative resection and tumor debulking operations are beneficial for some malignant tumors. Local ablative therapy can be tried on patients with small tumors who are not suitable candidates for open resectional surgery because of serious associated medical diseases or because of poor liver function. For patients with advanced malignancy, new treatment modalities in the form of hepatic artery transcatheter treatment or systemic therapy are on the horizon. Some of these treatment options show very promising results. Properly conducted randomized studies are required to evaluate these new treatment modalities, as well as those older treatment modalities for which there is insufficient data to determine their actual role in the management of patients with liver cancer.

Entities:  

Mesh:

Year:  2000        PMID: 11126378     DOI: 10.1002/1098-2388(200009)19:2<135::aid-ssu6>3.0.co;2-a

Source DB:  PubMed          Journal:  Semin Surg Oncol        ISSN: 1098-2388


  14 in total

Review 1.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

2.  Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.

Authors:  Hai-Hong Ye; Jia-Zhou Ye; Zhi-Bo Xie; Yu-Chong Peng; Jie Chen; Liang Ma; Tao Bai; Jun-Ze Chen; Zhan Lu; Hong-Gui Qin; Bang-De Xiang; Le-Qun Li
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

3.  General transcription factor IIb overexpression and a potential link to proliferation in human hepatocellular carcinoma.

Authors:  Liren Li; Aixian Zhang; Xiaolei Cao; Jing Chen; Yunfei Xia; Hui Zhao; Aiguo Shen
Journal:  Pathol Oncol Res       Date:  2012-10-05       Impact factor: 3.201

4.  Effective antitumour mono- and combination therapy by gene delivery of angiostatin-like molecule and interleukin-12 in a murine hepatoma model.

Authors:  Volker Schmitz; Lucia Tirado-Ledo; Esther Raskopf; Christian Rabe; Nicolas Wernert; Lin Wang; Jesús Prieto; Cheng Qian; Tilman Sauerbruch; Wolfgang H Caselmann
Journal:  Int J Colorectal Dis       Date:  2005-04-30       Impact factor: 2.571

Review 5.  Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.

Authors:  Yu-Peng Hong; Zi-Duo Li; Pankaj Prasoon; Qi Zhang
Journal:  World J Hepatol       Date:  2015-05-08

Review 6.  Liver transplantation for hepatocellular carcinoma.

Authors:  Sudeep Tanwar; Shahid A Khan; Vijay Paul Bob Grover; Catherine Gwilt; Belinda Smith; Ashley Brown
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

Review 7.  Extragastric manifestations of Helicobacter pylori infection: Possible role of bacterium in liver and pancreas diseases.

Authors:  Elizabeth Ma Rabelo-Gonçalves; Bruna M Roesler; José Mr Zeitune
Journal:  World J Hepatol       Date:  2015-12-28

8.  Chemo-embolization for unresectable hepatocellular carcinoma with different sizes of embolization particles.

Authors:  Nikhil B Amesur; Albert B Zajko; Brian I Carr
Journal:  Dig Dis Sci       Date:  2007-11-29       Impact factor: 3.199

9.  131Iodine-DEM TACE vs. conventional TACE in cirrhotic patients with hepatocellular carcinoma: a single center experiment.

Authors:  Yu Ma; Ligeng Duan; Lin Li; Wusheng Lu; Bo Li; Xiaoli Chen
Journal:  J Gastrointest Oncol       Date:  2021-04

10.  Electrocoagulation for liver metastases.

Authors:  Dawid Storman; Mateusz J Swierz; Robert P Riemsma; Robert Wolff; Jerzy W Mitus; Michal Pedziwiatr; Jos Kleijnen; Malgorzata M Bala
Journal:  Cochrane Database Syst Rev       Date:  2021-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.